<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1609">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05140213</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL21_0685</org_study_id>
    <nct_id>NCT05140213</nct_id>
  </id_info>
  <brief_title>Mortality of Severe Sepsis at 30 Days Before/After Implementation of Prescription Tool</brief_title>
  <official_title>EVALUATION OF 30-DAY MORTALITY AFTER A VISIT TO THE LAPEYRONIE ADULT EMERGENCY DEPARTMENT OF THE CHU MONTPELLIER FOR SEPSIS OR SEPTIC SHOCK: A STUDY BEFORE/AFTER THE IMPLEMENTATION OF AN ANTI-INFECTIOUS PRESCRIPTION AID</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anti-infective strategy is a major public health problem. This is a before-and-after study of&#xD;
      an anti-infectious prescription tool with a comparison of mortality at 30 days (then 3 and 6&#xD;
      months) between the two inclusion phases of 6 months each.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2020</start_date>
  <completion_date type="Actual">August 30, 2021</completion_date>
  <primary_completion_date type="Actual">August 12, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Numbers of patient 30-day mortality</measure>
    <time_frame>30 day</time_frame>
    <description>patient survival at 30 days</description>
  </primary_outcome>
  <other_outcome>
    <measure>Numbers of patient 90-day mortality</measure>
    <time_frame>90 days</time_frame>
    <description>patient survival at 90 days</description>
  </other_outcome>
  <other_outcome>
    <measure>Numbers of patient 6 months mortality</measure>
    <time_frame>6 months</time_frame>
    <description>patient survival at 6 months</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">371</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Group 1 : Before</arm_group_label>
    <description>&quot;Before&quot; phase including 186 patients patients included before the implementation of the prescription support tool</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 : After</arm_group_label>
    <description>&quot;After&quot; phase including 185 patients patients included after the implementation of the prescription support tool</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Anti-infectious prescription support tool</intervention_name>
    <description>implementation of a pocket notebook with current anti-infectious recommendations in the emergency department Patients were kept under surveillance for at least one hour before discharge.&#xD;
Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief.</description>
    <arm_group_label>Group 1 : Before</arm_group_label>
    <arm_group_label>Group 2 : After</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Major patients with severe sepsis in the Montpellier emergency department&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Major patients&#xD;
&#xD;
          -  Sepsis or septic shock&#xD;
&#xD;
          -  Oral consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  minor patients&#xD;
&#xD;
          -  death before antibiotherapy&#xD;
&#xD;
          -  care limitations&#xD;
&#xD;
          -  pre-hospital antibiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamza GHOMRANI, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uh Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 17, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult patients</keyword>
  <keyword>Probabilistic antibiotic therapy to be initiated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

